Edgen Stock·Sep 08 2025, 08:09戻る
戻る
Eli Lilly’s Orforglipron Success Navigates Complex GLP-1 Market Dynamics
Edgen Stock·Sep 08 2025, 08:09
[1] Why weight-loss 'wonder drugs' aren't 'wonder stocks' — yet (https://finance.yahoo.com/news/why-weight-los ...)[2] Eli Lilly eyes orforglipron approval after Phase III diabetes trial success (https://vertexaisearch.cloud.google.com/groun ...)[3] Why obesity stocks are struggling in 2025? - Investing.com (https://vertexaisearch.cloud.google.com/groun ...)